Viking Therapeutics begins Phase 1 VK3019 obesity trial
- Viking Therapeutics (NASDAQ:VKTX) initiated a Phase 1 trial of VK3019, a dual amylin and calcitonin receptor agonist.
- The study is evaluating safety, tolerability, pharmacokinetics, and early effects on body weight in adults with BMI ≥30.
- The program expands Viking’s broader obesity pipeline alongside VK2735 and other metabolic disease candidates.
Viking Therapeutics (NASDAQ:VKTX) has started a Phase 1 single ascending dose study of VK3019 in healthy adults with a body mass index of 30 or higher.
The randomized, double-blind, placebo-controlled trial is designed to evaluate safety, tolerability, pharmacokinetics, and exploratory effects on body weight reduction.
VK3019 is a dual amylin and calcitonin receptor agonist being developed as part of Viking’s expanding pipeline in obesity and metabolic diseases.
The candidate adds to Viking’s broader obesity portfolio, which includes Phase 3 VANQUISH trials of VK2735 and planned oral VK2735 development programs.
Viking is also advancing additional pipeline assets including VK2809 for metabolic dysfunction-associated steatohepatitis (MASH/NASH) and VK0214 for X-linked adrenoleukodystrophy.
More from United States
AbbVie revenue increases 10.3% to $17.4 billion in third quarter
Sensient Q3 revenue rockets 10.6% to $455.8 million
Cameco Q3 adjusted loss reaches CA$2 million as uranium output falls
Kite Realty Q3 loss narrows to $13.3 million as NOI grows
Largo cuts 2026 vanadium production outlook to 9,500–10,500 tonnes
nVent Q3 sales jump 44% as shares fall despite higher revenue
